

# Alexandre P Zavascki

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/158541/publications.pdf>

Version: 2024-02-01

134  
papers

5,514  
citations

109321

35  
h-index

91884

69  
g-index

134  
all docs

134  
docs citations

134  
times ranked

5810  
citing authors

| #  | ARTICLE  | IF   | CITATIONS |
|----|--|------|-----------|
| 1  | Convalescent plasma for COVID-19 in hospitalised patients: an open-label, randomised clinical trial. <i>European Respiratory Journal</i> , 2022, 59, 2101471.  | 6.7  | 55        |
| 2  | Diagnostic accuracy of a SARS-CoV-2 rapid test and optimal time for seropositivity according to the onset of symptoms. <i>Cadernos De Saude Publica</i> , 2022, 38, e00069921.   | 1.0  | 1         |
| 3  | Evaluation of Clinical Course of Gamma (P.1) Variant of Concern versus Lineages in Hospitalized Patients with COVID-19 in a Reference Center in Brazil. <i>American Journal of Tropical Medicine and Hygiene</i> , 2022, 107, 245-251.   | 1.4  | 3         |
| 4  | Increased frequency of blaNDM in a tertiary care hospital in southern Brazil. <i>Brazilian Journal of Microbiology</i> , 2021, 52, 299-301.  | 2.0  | 7         |
| 5  | Amikacin for the treatment of carbapenem-resistant <i>Klebsiella pneumoniae</i> infections: clinical efficacy and toxicity. <i>Brazilian Journal of Microbiology</i> , 2021, 52, 1913-1919.  | 2.0  | 9         |
| 6  | Urgent need for evaluation of point-of-care tests as an RT-PCR-sparing strategy for the diagnosis of Covid-19 in symptomatic patients. <i>Epidemiology and Infection</i> , 2021, 149, e35.   | 2.1  | 2         |
| 7  | Assessing the predictive performance of population pharmacokinetic models for intravenous polymyxin B in critically ill patients. <i>CPT: Pharmacometrics and Systems Pharmacology</i> , 2021, 10, 1525-1537.  | 2.5  | 15        |
| 8  | 1266. Melatonin for Renal Protection of Patients Treated with Polymyxin B: A Double Blind Randomized Clinical Trial. <i>Open Forum Infectious Diseases</i> , 2021, 8, S721-S721.   | 0.9  | 0         |
| 9  | Vancomycin and creatinine determination in dried blood spots: Analytical validation and clinical assessment. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2020, 1137, 121897.   | 2.3  | 19        |
| 10 | Clinical usefulness of tomographic standards for COVID-19 pneumonia diagnosis: Experience from a Brazilian reference center. <i>Brazilian Journal of Infectious Diseases</i> , 2020, 24, 524-533.  | 0.6  | 8         |
| 11 | First report of IMP-1 in a clinical isolate of <i>Escherichia coli</i> in Latin America. <i>Infection Control and Hospital Epidemiology</i> , 2020, 41, 997-998.   | 1.8  | 3         |
| 12 | Clinical Characteristics of Covid-19 in China. <i>New England Journal of Medicine</i> , 2020, 382, 1859-1862.  | 27.0 | 275       |
| 13 | Novel Cassette Assay To Quantify the Outer Membrane Permeability of Five $\beta$ -Lactams Simultaneously in Carbapenem-Resistant <i>Klebsiella pneumoniae</i> and <i>Enterobacter cloacae</i> . <i>MBio</i> , 2020, 11, .  | 4.1  | 17        |
| 14 | Performance of polymyxin B Etest in a setting of high prevalence of KPC-producing <i>Klebsiella pneumoniae</i> . <i>Journal of Global Antimicrobial Resistance</i> , 2020, 22, 40-42.  | 2.2  | 2         |
| 15 | Four Decades of $\beta$ -Lactam Antibiotic Pharmacokinetics in Cystic Fibrosis. <i>Clinical Pharmacokinetics</i> , 2019, 58, 143-156.  | 3.5  | 15        |
| 16 | Clinical Use of Polymyxin B. <i>Advances in Experimental Medicine and Biology</i> , 2019, 1145, 197-218.   | 1.6  | 25        |
| 17 | Can ceftolozane-tazobactam treat nosocomial pneumonia?. <i>Lancet Infectious Diseases</i> , The, 2019, 19, 1266-1267.  | 9.1  | 2         |
| 18 | International Consensus Guidelines for the Optimal Use of the Polymyxins: Endorsed by the American College of Clinical Pharmacy (ACCP), European Society of Clinical Microbiology and Infectious Diseases (ESCMID), Infectious Diseases Society of America (IDSA), International Society for Antimicrobial Pharmacology (ISAP), Society of Critical Care Medicine (SCCM), and Society of Infectious Diseases Pharmacists (SIDP). <i>Pharmacotherapy</i> , 2019, 39, 10-39. | 2.6  | 545       |

| #  | ARTICLE   | IF  | CITATIONS |
|----|---|-----|-----------|
| 19 | Comparable Efficacy and Better Safety of Double $\beta$ -Lactam Combination Therapy versus $\beta$ -Lactam plus Aminoglycoside in Gram-Negative Bacteria in Randomized, Controlled Trials. <i>Antimicrobial Agents and Chemotherapy</i> , 2019, 63, .                     | 3.2 | 24        |
| 20 | Detection of Enterobacterales resistant to polymyxins using Rapid Polymyxins NP test. <i>Brazilian Journal of Microbiology</i> , 2019, 50, 425-428.   | 2.0 | 12        |
| 21 | Polymyxin Acute Kidney Injury: Dosing and Other Strategies to Reduce Toxicity. <i>Antibiotics</i> , 2019, 8, 24.  | 3.7 | 76        |
| 22 | A Cohort Study of the Impact of Carbapenem-Resistant Enterobacteriaceae Infections on Mortality of Patients Presenting with Sepsis. <i>MSphere</i> , 2019, 4, .   | 2.9 | 35        |
| 23 | Combination therapy with polymyxin B for carbapenemase-producing <i>Klebsiella pneumoniae</i> bloodstream infection. <i>International Journal of Antimicrobial Agents</i> , 2019, 53, 152-157.  | 2.5 | 35        |
| 24 | Impact of polymyxin-B-associated acute kidney injury in 1-year mortality and renal function recovery. <i>International Journal of Antimicrobial Agents</i> , 2018, 52, 86-89.   | 2.5 | 8         |
| 25 | Colistin versus colistin plus meropenem for severe infections. <i>Lancet Infectious Diseases</i> , The, 2018, 18, 493-494.  | 9.1 | 1         |
| 26 | Emergence of polymyxin B resistance in a polymyxin B-susceptible KPC-producing <i>Klebsiella pneumoniae</i> causing bloodstream infection in a neutropenic patient during polymyxin B therapy. <i>Diagnostic Microbiology and Infectious Disease</i> , 2018, 90, 134-138. | 1.8 | 13        |
| 27 | Acquisition of the <i>mcr-1</i> gene by a high-risk clone of KPC-2-producing <i>Klebsiella pneumoniae</i> ST437/CC258, Brazil. <i>Diagnostic Microbiology and Infectious Disease</i> , 2018, 90, 132-133.   | 1.8 | 37        |
| 28 | Severe Infusion-Related Adverse Events and Renal Failure in Patients Receiving High-Dose Intravenous Polymyxin B. <i>Antimicrobial Agents and Chemotherapy</i> , 2018, 62, .  | 3.2 | 36        |
| 29 | Effect of polymyxin B-containing regimens on renal function for the treatment of carbapenem-resistant Enterobacteriaceae mediastinitis. <i>Brazilian Journal of Infectious Diseases</i> , 2018, 22, 51-54.  | 0.6 | 1         |
| 30 | KPC-producing <i>Klebsiella pneumoniae</i> bloodstream isolates from Brazilian hospitals: What (still) remains active?. <i>Journal of Global Antimicrobial Resistance</i> , 2018, 15, 173-177.  | 2.2 | 7         |
| 31 | Dissemination of blaOXA-370 is mediated by IncX plasmids and the Tn6435 transposon. <i>European Journal of Clinical Microbiology and Infectious Diseases</i> , 2018, 37, 2165-2169.   | 2.9 | 2         |
| 32 | Low doses of colistimethate: Don't rush in!. <i>Clinical Infectious Diseases</i> , 2017, 64, ciw818.  | 5.8 | 1         |
| 33 | Characterization of Transformants Obtained From NDM-1-Producing Enterobacteriaceae in Brazil. <i>Infection Control and Hospital Epidemiology</i> , 2017, 38, 634-636.   | 1.8 | 3         |
| 34 | Detection of OXA-370 directly from rectal swabs and blood culture vials using an immunochromatographic assay. <i>Journal of Microbiological Methods</i> , 2017, 139, 92-94.   | 1.6 | 8         |
| 35 | Aminoglycosides against carbapenem-resistant Enterobacteriaceae in the critically ill: the pitfalls of aminoglycoside susceptibility. <i>Expert Review of Anti-Infective Therapy</i> , 2017, 15, 519-526.   | 4.4 | 44        |
| 36 | Nephrotoxicity of Polymyxins: Is There Any Difference between Colistimethate and Polymyxin B?. <i>Antimicrobial Agents and Chemotherapy</i> , 2017, 61, .   | 3.2 | 152       |

| #  | ARTICLE   | IF  | CITATIONS |
|----|---|-----|-----------|
| 37 | Co-occurrence of <i>mcr-1</i> and <i>bla</i> KPC-2 in a clinical isolate of <i>Escherichia coli</i> in Brazil. <i>Journal of Antimicrobial Chemotherapy</i> , 2017, 72, 2404-2406.  | 3.0 | 26        |
| 38 | Characteristics of Enterobacteriaceae Isolates Coharboring Distinct Carbapenemase Genes. <i>Infection Control and Hospital Epidemiology</i> , 2017, 38, 1123-1126.  | 1.8 | 2         |
| 39 | Polymyxin B Resistance in Carbapenem-Resistant <i>Klebsiella pneumoniae</i> , São Paulo, Brazil. <i>Emerging Infectious Diseases</i> , 2016, 22, 1849-1851.   | 4.3 | 45        |
| 40 | Histopathological findings of pigmented lesion and recovery of natural skin colour in a patient with polymyxin B-associated diffuse hyperpigmentation. <i>International Journal of Antimicrobial Agents</i> , 2016, 48, 579-580.  | 2.5 | 16        |
| 41 | Clinical features and mortality of patients on renal replacement therapy receiving polymyxin B. <i>International Journal of Antimicrobial Agents</i> , 2016, 47, 146-150.   | 2.5 | 18        |
| 42 | Multicenter Prospective Cohort Study of Renal Failure in Patients Treated with Colistin versus Polymyxin B. <i>Antimicrobial Agents and Chemotherapy</i> , 2016, 60, 2443-2449.   | 3.2 | 104       |
| 43 | Letter to the editor: <i>Escherichia coli</i> harbouring <i>mcr-1</i> gene isolated from poultry not exposed to polymyxins in Brazil. <i>Eurosurveillance</i> , 2016, 21, .   | 7.0 | 34        |
| 44 | <i>Lactobacillus rhamnosus</i> bacteremia in a kidney transplant recipient. <i>Transplant Infectious Disease</i> , 2015, 17, 610-612.   | 1.7 | 11        |
| 45 | Risk factors for acute kidney injury (AKI) in patients treated with polymyxin B and influence of AKI on mortality: a multicentre prospective cohort study. <i>Journal of Antimicrobial Chemotherapy</i> , 2015, 70, 1552-1557.  | 3.0 | 98        |
| 46 | Emergence of NDM-1-producing <i>Acinetobacter pittii</i> in Brazil. <i>International Journal of Antimicrobial Agents</i> , 2015, 45, 444-445.   | 2.5 | 31        |
| 47 | <i>Streptococcus pneumoniae</i> appendicitis in an adult patient. <i>American Journal of Emergency Medicine</i> , 2015, 33, 990.e1-990.e3.  | 1.6 | 4         |
| 48 | Head and Neck Hyperpigmentation Probably Associated With Polymyxin B Therapy. <i>Annals of Pharmacotherapy</i> , 2015, 49, 1171-1172.   | 1.9 | 20        |
| 49 | Activity of Antimicrobial Combinations against KPC-2-Producing <i>Klebsiella pneumoniae</i> in a Rat Model and Time-Kill Assay. <i>Antimicrobial Agents and Chemotherapy</i> , 2015, 59, 4301-4304.   | 3.2 | 23        |
| 50 | High Endemic Rates of OXA-23-Producing Carbapenem-Resistant <i>Acinetobacter baumannii</i> Isolates Caused by the Persistence of Major Clones in Hospitals in a Brazilian City 5 Years After an Outbreak. <i>Infection Control and Hospital Epidemiology</i> , 2015, 36, 860-862.                 | 1.8 | 13        |
| 51 | <i>In Vitro</i> Activity of Polymyxin B plus Imipenem, Meropenem, or Tigecycline against KPC-2-Producing Enterobacteriaceae with High MICs for These Antimicrobials. <i>Antimicrobial Agents and Chemotherapy</i> , 2015, 59, 3596-3597.  | 3.2 | 16        |
| 52 | Characterization of Tn <i>3000</i> , a Transposon Responsible for <i>bla</i> <sub>NDM-1</sub> Dissemination among Enterobacteriaceae in Brazil, Nepal, Morocco, and India. <i>Antimicrobial Agents and Chemotherapy</i> , 2015, 59, 7387-7395.  | 3.2 | 70        |
| 53 | The changing epidemiology of <i>Acinetobacter</i> spp. producing OXA carbapenemases causing bloodstream infections in Brazil: a BrasNet report. <i>Diagnostic Microbiology and Infectious Disease</i> , 2015, 83, 382-385.  | 1.8 | 50        |
| 54 | Polymyxin B in Combination with Antimicrobials Lacking <i>In Vitro</i> Activity versus Polymyxin B in Monotherapy in Critically Ill Patients with <i>Acinetobacter baumannii</i> or <i>Pseudomonas aeruginosa</i> Infections. <i>Antimicrobial Agents and Chemotherapy</i> , 2015, 59, 6575-6580. | 3.2 | 58        |

| #  | ARTICLE  | IF  | CITATIONS |
|----|--|-----|-----------|
| 55 | Performance of Quantification of Modified Hodge Test: An Evaluation with <i>Klebsiella pneumoniae</i> Carbapenemase-Producing Enterobacteriaceae Isolates. <i>BioMed Research International</i> , 2014, 2014, 1-6.   | 1.9 | 10        |
| 56 | Detection of <i>bla</i> <sub>GES-5</sub> in Carbapenem-Resistant <i>Kluyvera intermedia</i> Isolates Recovered from the Hospital Environment. <i>Antimicrobial Agents and Chemotherapy</i> , 2014, 58, 622-623.  | 3.2 | 21        |
| 57 | Risk factors for acute kidney injury in patients treated with polymyxin B or colistin methanesulfonate sodium. <i>International Journal of Antimicrobial Agents</i> , 2014, 43, 349-352.   | 2.5 | 120       |
| 58 | Polymyxins for the treatment of extensively-drug-resistant Gram-negative bacteria: from pharmacokinetics to bedside. <i>Expert Review of Anti-Infective Therapy</i> , 2014, 12, 531-533.   | 4.4 | 12        |
| 59 | Heteroresistance to Carbapenems in New Delhi Metallo- $\beta$ -Lactamase-1 Producing Isolates: A Challenge for Detection?. <i>Infection Control and Hospital Epidemiology</i> , 2014, 35, 751-752.   | 1.8 | 7         |
| 60 | Effect of cefepime dose on mortality of patients with Gram-negative bacterial bloodstream infections: a prospective cohort study. <i>Journal of Antimicrobial Chemotherapy</i> , 2014, 69, 1681-1687.  | 3.0 | 17        |
| 61 | Detection of OXA-370, an OXA-48-Related Class D $\beta$ -Lactamase, in <i>Enterobacter hormaechei</i> from Brazil. <i>Antimicrobial Agents and Chemotherapy</i> , 2014, 58, 3566-3567.   | 3.2 | 33        |
| 62 | Carbapenem-resistant GES-5-producing <i>Klebsiella pneumoniae</i> in Southern Brazil. <i>Brazilian Journal of Infectious Diseases</i> , 2014, 18, 231-232.   | 0.6 | 12        |
| 63 | Emergence of NDM-1-producing Enterobacteriaceae in Porto Alegre, Brazil. <i>International Journal of Infectious Diseases</i> , 2014, 25, 79-81.  | 3.3 | 44        |
| 64 | PCR to detect <i>Mycobacterium tuberculosis</i> in respiratory tract samples: evaluation of clinical data. <i>Epidemiology and Infection</i> , 2014, 142, 1517-1523.   | 2.1 | 5         |
| 65 | Current Status of <i>Pseudomonas aeruginosa</i> Vaccine. <i>Current Pharmaceutical Biotechnology</i> , 2014, 14, 951-959.  | 1.6 | 4         |
| 66 | Comparison of polymyxin B with other antimicrobials in the treatment of ventilator-associated pneumonia and tracheobronchitis caused by <i>Pseudomonas aeruginosa</i> or <i>Acinetobacter baumannii</i> . <i>Infection</i> , 2013, 41, 321-328.                  | 4.7 | 24        |
| 67 | Hetero- and adaptive resistance to polymyxin B in OXA-23-producing carbapenem-resistant <i>Acinetobacter baumannii</i> isolates. <i>Annals of Clinical Microbiology and Antimicrobials</i> , 2013, 12, 15.   | 3.8 | 30        |
| 68 | Septic arthritis caused by <i>Neisseria pharyngis</i> in an elderly patient with knee prosthesis. <i>Rheumatology International</i> , 2013, 33, 541-542.   | 3.0 | 1         |
| 69 | In vitro activity of non-bactericidal concentrations of polymyxin B in combination with other antimicrobials against OXA-23-producing carbapenem-resistant <i>Acinetobacter baumannii</i> . <i>Brazilian Journal of Infectious Diseases</i> , 2013, 17, 502-504. | 0.6 | 5         |
| 70 | Molecular characterization of <i>Klebsiella pneumoniae</i> carbapenemase-producing isolates in southern Brazil. <i>Journal of Medical Microbiology</i> , 2013, 62, 1721-1727.  | 1.8 | 21        |
| 71 | Reply to Pai. <i>Clinical Infectious Diseases</i> , 2013, 57, 1786-1786.   | 5.8 | 2         |
| 72 | Combination therapy for carbapenem-resistant Gram-negative bacteria. <i>Expert Review of Anti-Infective Therapy</i> , 2013, 11, 1333-1353.   | 4.4 | 112       |

| #  | ARTICLE   | IF  | CITATIONS |
|----|---|-----|-----------|
| 73 | Direct detection of blaOXA-23 gene from endotracheal aspirates by real time PCR. Brazilian Journal of Infectious Diseases, 2013, 17, 493-494.   | 0.6 | 1         |
| 74 | Evaluation of heteroresistance to polymyxin B among carbapenem-susceptible and -resistant <i>Pseudomonas aeruginosa</i> . Journal of Medical Microbiology, 2013, 62, 1184-1189.   | 1.8 | 48        |
| 75 | Population Pharmacokinetics of Intravenous Polymyxin B in Critically Ill Patients: Implications for Selection of Dosage Regimens. Clinical Infectious Diseases, 2013, 57, 524-531.  | 5.8 | 351       |
| 76 | Pharmacokinetics of polymyxin B in patients on continuous venovenous haemodialysis. Journal of Antimicrobial Chemotherapy, 2013, 68, 674-677.   | 3.0 | 63        |
| 77 | <i>Paecilomyces variotii</i> as an Emergent Pathogenic Agent of Pneumonia. Case Reports in Infectious Diseases, 2013, 2013, 1-3.  | 0.5 | 32        |
| 78 | Detection of blaKPC-2 in a carbapenem-resistant <i>Kluyvera georgiana</i> . Journal of Antimicrobial Chemotherapy, 2012, 67, 2776-2777.   | 3.0 | 15        |
| 79 | Outbreak of Carbapenem-Resistant <i>Providencia stuartii</i> in an Intensive Care Unit. Infection Control and Hospital Epidemiology, 2012, 33, 627-630.   | 1.8 | 28        |
| 80 | Macrolides decrease the minimal inhibitory concentration of anti-pseudomonal agents against <i>Pseudomonas aeruginosa</i> from cystic fibrosis patients in biofilm. BMC Microbiology, 2012, 12, 196.  | 3.3 | 46        |
| 81 | Risk factors for KPC-producing <i>Klebsiella pneumoniae</i> bacteremia. Brazilian Journal of Infectious Diseases, 2012, 16, 416-419.  | 0.6 | 49        |
| 82 | Polymyxin B Consumption and Incidence of Gram-Negative Bacteria Intrinsically Resistant to Polymyxins. Infection Control and Hospital Epidemiology, 2012, 33, 536-537.  | 1.8 | 1         |
| 83 | Lack of methicillin-resistant <i>Staphylococcus aureus</i> nasal carriage among patients at a primary-healthcare unit in Porto Alegre, Brazil. Revista Do Instituto De Medicina Tropical De Sao Paulo, 2011, 53, 197-199.   | 1.1 | 3         |
| 84 | Polymyxin B versus other antimicrobials for the treatment of <i>Pseudomonas aeruginosa</i> bacteraemia. Journal of Antimicrobial Chemotherapy, 2011, 66, 175-179.   | 3.0 | 55        |
| 85 | Dose Adjustment of Polymyxins for Renal Insufficiency. Antimicrobial Agents and Chemotherapy, 2011, 55, 4940-4940.  | 3.2 | 6         |
| 86 | Risk factors for 30-day mortality in patients with carbapenem-resistant <i>Acinetobacter baumannii</i> during an outbreak in an intensive care unit. Epidemiology and Infection, 2011, 139, 411-418.  | 2.1 | 13        |
| 87 | The impact of polymyxin B dosage on in-hospital mortality of patients treated with this antibiotic. Journal of Antimicrobial Chemotherapy, 2010, 65, 2231-2237.   | 3.0 | 101       |
| 88 | Vancomycin MIC for Methicillin-Resistant Coagulase-Negative <i>Staphylococcus</i> Isolates: Evaluation of the Broth Microdilution and Etest Methods. Journal of Clinical Microbiology, 2010, 48, 4652-4654.   | 3.9 | 18        |
| 89 | High frequency of $\beta$ -lactam susceptibility in CTX-M-type extended-spectrum- $\beta$ -lactamase-producing <i>Klebsiella pneumoniae</i> , <i>Escherichia coli</i> and <i>Proteus mirabilis</i> according to the new CLSI recommendations. Journal of Antimicrobial Chemotherapy, 2010, 65, 2481-2483. | 3.0 | 6         |
| 90 | Multidrug-resistant <i>Pseudomonas aeruginosa</i> and <i>Acinetobacter baumannii</i> : resistance mechanisms and implications for therapy. Expert Review of Anti-Infective Therapy, 2010, 8, 71-93.   | 4.4 | 256       |

| #   | ARTICLE   | IF   | CITATIONS |
|-----|---|------|-----------|
| 91  | KPC-2-producing <i>Klebsiella pneumoniae</i> in Brazil: A widespread threat in waiting?. <i>International Journal of Infectious Diseases</i> , 2010, 14, e539-e540.   | 3.3  | 17        |
| 92  | <i>Corynebacterium striatum</i> infecting a malignant cutaneous lesion: the emergence of an opportunistic pathogen. <i>Revista Do Instituto De Medicina Tropical De Sao Paulo</i> , 2009, 51, 115-116.  | 1.1  | 21        |
| 93  | Editor's Correspondence. <i>Archives of Internal Medicine</i> , 2009, 169, 809.   | 3.8  | 0         |
| 94  | Risk factors for and mortality of extended-spectrum- $\beta$ -lactamase-producing <i>Klebsiella pneumoniae</i> and <i>Escherichia coli</i> nosocomial bloodstream infections. <i>Revista Do Instituto De Medicina Tropical De Sao Paulo</i> , 2009, 51, 211-216.  | 1.1  | 30        |
| 95  | Reply to Kunin. <i>Clinical Infectious Diseases</i> , 2009, 48, 843-844.  | 5.8  | 0         |
| 96  | How Efficient Is Procalcitonin-Guided Antibiotic Use in Acute Respiratory Tract Infections in Primary Care?. <i>Archives of Internal Medicine</i> , 2009, 169, 1241.  | 3.8  | 1         |
| 97  | Stable Polymyxin B Susceptibility to <i>Pseudomonas aeruginosa</i> and <i>Acinetobacter</i> spp. despite Persistent Recovery of These Organisms from Respiratory Secretions of Patients with Ventilator-Associated Pneumonia Treated with This Drug. <i>Journal of Clinical Microbiology</i> , 2009, 47, 3064-3065. | 3.9  | 7         |
| 98  | Scanning electron microscopy of scutular tinea. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2009, 23, 325-327.  | 2.4  | 3         |
| 99  | Advances in the way of dealing with antibiotic exposure in studies assessing risk factors for drug-resistant pathogens. <i>Diagnostic Microbiology and Infectious Disease</i> , 2009, 64, 102.  | 1.8  | 1         |
| 100 | Clinical and molecular epidemiology of methicillin-resistant <i>Staphylococcus aureus</i> carrying SCCmecIV in a university hospital in Porto Alegre, Brazil. <i>Diagnostic Microbiology and Infectious Disease</i> , 2009, 65, 457-461.  | 1.8  | 25        |
| 101 | KPC-2-producing <i>Enterobacter cloacae</i> in two cities from Southern Brazil. <i>International Journal of Antimicrobial Agents</i> , 2009, 34, 286-288.   | 2.5  | 19        |
| 102 | Development and validation of a reversed-phase high-performance liquid chromatography assay for polymyxin B in human plasma--authors' response. <i>Journal of Antimicrobial Chemotherapy</i> , 2009, 63, 628-629.   | 3.0  | 12        |
| 103 | Treatment of extensively drug-resistant tuberculosis. <i>Lancet, The</i> , 2009, 373, 27.   | 13.7 | 2         |
| 104 | Indications of carbapenem resistance evolution through heteroresistance as an intermediate stage in <i>Acinetobacter baumannii</i> after carbapenem administration. <i>Revista Do Instituto De Medicina Tropical De Sao Paulo</i> , 2009, 51, 111-113.  | 1.1  | 13        |
| 105 | Caution when reconsidering empiric antimicrobial therapy for methicillin-resistant <i>Staphylococcus aureus</i> skin and soft-tissue infections. <i>American Journal of Surgery</i> , 2008, 196, 618-619.   | 1.8  | 0         |
| 106 | Intravenous colistimethate for multidrug-resistant Gram-negative bacteria. <i>Lancet Infectious Diseases, The</i> , 2008, 8, 403-405.   | 9.1  | 16        |
| 107 | Nosocomial bloodstream infections due to metallo- $\beta$ -lactamase-producing <i>Pseudomonas aeruginosa</i> . <i>Journal of Antimicrobial Chemotherapy</i> , 2008, 61, 1183-1185.  | 3.0  | 11        |
| 108 | Development and validation of a reversed-phase high-performance liquid chromatography assay for polymyxin B in human plasma. <i>Journal of Antimicrobial Chemotherapy</i> , 2008, 62, 1009-1014.  | 3.0  | 38        |

| #   | ARTICLE   | IF  | CITATIONS |
|-----|---|-----|-----------|
| 109 | Pharmacokinetics of Intravenous Polymyxin B in Critically Ill Patients. <i>Clinical Infectious Diseases</i> , 2008, 47, 1298-1304.  | 5.8 | 208       |
| 110 | Cystic Fibrosis Patient with <i>Burkholderia pseudomallei</i> Infection Acquired in Brazil. <i>Journal of Clinical Microbiology</i> , 2007, 45, 4077-4080.  | 3.9 | 16        |
| 111 | Is High Minimal Inhibitory Concentration of Vancomycin a Predictor of Poor Response in MRSA Infections?. <i>Archives of Internal Medicine</i> , 2007, 167, 1206.  | 3.8 | 0         |
| 112 | Predictors of Repeat Pregnancy Among HIV-1-Infected Women. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2007, 45, 368-369.   | 2.1 | 0         |
| 113 | High prevalence of metallo- $\beta$ -lactamase-mediated resistance challenging antimicrobial therapy against <i>Pseudomonas aeruginosa</i> in a Brazilian teaching hospital. <i>Epidemiology and Infection</i> , 2007, 135, 343-345.  | 2.1 | 9         |
| 114 | The need for reappraisal of AIDS score weight of Charlson comorbidity index. <i>Journal of Clinical Epidemiology</i> , 2007, 60, 867-868.   | 5.0 | 47        |
| 115 | Polymyxin B for the treatment of multidrug-resistant pathogens: a critical review. <i>Journal of Antimicrobial Chemotherapy</i> , 2007, 60, 1206-1215.  | 3.0 | 695       |
| 116 | Stable carbapenem susceptibility rates among multidrug-resistant <i>Acinetobacter</i> spp. strains in a setting of high prevalence of carbapenem-resistant <i>Pseudomonas aeruginosa</i> . <i>International Journal of Antimicrobial Agents</i> , 2007, 30, 187-189.                                      | 2.5 | 6         |
| 117 | Determining Risk Factors for Infection with Influenza A (H5N1). <i>Emerging Infectious Diseases</i> , 2007, 13, 955-956.  | 4.3 | 3         |
| 118 | <i>Pneumocystis jiroveci</i> thyroiditis: report of 15 cases in the literature. <i>Mycoses</i> , 2007, 50, 443-446.   | 4.0 | 18        |
| 119 | Dissemination of <i>Pseudomonas aeruginosa</i> Producing SPM-1-like and IMP-1-like Metallo- $\beta$ -lactamases in Hospitals from Southern Brazil. <i>Infection</i> , 2007, 35, 457-460.  | 4.7 | 47        |
| 120 | Ocurrence of blaSPM-1 and blaIMP-1 genes of metallo-beta-lactamases in clinical isolates of <i>Pseudomonas aeruginosa</i> from three university hospitals in the city of Porto Alegre, Brazil. <i>Brazilian Journal of Microbiology</i> , 2007, 38, 108-109.  | 2.0 | 11        |
| 121 | Continuous intravenous administration of antibiotics. <i>Lancet Infectious Diseases</i> , The, 2006, 6, 259.  | 9.1 | 1         |
| 122 | Reduction in Incidence of Nosocomial Methicillin-Resistant <i>Staphylococcus aureus</i> (MRSA) Infection in an Intensive Care Unit: Role of Treatment With Mupirocin Ointment and Chlorhexidine Baths for Nasal Carriers of MRSA. <i>Infection Control and Hospital Epidemiology</i> , 2006, 27, 185-187. | 1.8 | 100       |
| 123 | Reappraisal of <i>Pseudomonas aeruginosa</i> hospital-acquired pneumonia mortality in the era of metallo-beta-lactamase-mediated multidrug resistance: a prospective observational study. <i>Critical Care</i> , 2006, 10, R114.  | 5.8 | 52        |
| 124 | Fungal Thyroiditis: An Overview. <i>Mycopathologia</i> , 2006, 161, 129-139.  | 3.1 | 50        |
| 125 | Intracranial Tuberculomas in an Immunocompetent Patient Mimicking Brain Metastasis of Unknown Origin. <i>Infection</i> , 2006, 34, 181-182.   | 4.7 | 11        |
| 126 | First Case Report of <i>Neisseria lactamica</i> Causing Cavitory Lung Disease in an Adult Organ Transplant Recipient. <i>Journal of Clinical Microbiology</i> , 2006, 44, 2666-2668.  | 3.9 | 12        |



| #   | ARTICLE  | IF  | CITATIONS |
|-----|--|-----|-----------|
| 127 | Risk factors for nosocomial infections due to <i>Pseudomonas aeruginosa</i> producing metallo- $\beta$ -lactamase in two tertiary-care teaching hospitals. <i>Journal of Antimicrobial Chemotherapy</i> , 2006, 58, 882-885. | 3.0 | 40        |
| 128 | The influence of metallo- $\beta$ -lactamase production on mortality in nosocomial <i>Pseudomonas aeruginosa</i> infections. <i>Journal of Antimicrobial Chemotherapy</i> , 2006, 58, 387-392.                               | 3.0 | 99        |
| 129 | Treatment of multidrug-resistant <i>Pseudomonas aeruginosa</i> infections: more attention required to in-vitro studies. <i>Clinical Microbiology and Infection</i> , 2005, 11, 856-857.                                      | 6.0 | 0         |
| 130 | Outbreak of carbapenem-resistant <i>Pseudomonas aeruginosa</i> producing SPM-1 metallo- $\beta$ -lactamase in a teaching hospital in southern Brazil. <i>Journal of Antimicrobial Chemotherapy</i> , 2005, 56, 1148-1151.    | 3.0 | 78        |
| 131 | Risk factors for imipenem-resistant <i>Pseudomonas aeruginosa</i> : a comparative analysis of two case-control studies in hospitalized patients. <i>Journal of Hospital Infection</i> , 2005, 59, 96-101.                    | 2.9 | 68        |
| 132 | Assessing Risk Factors for Acquiring Antimicrobial-Resistant Pathogens: A Time for a Comparative Approach. <i>Clinical Infectious Diseases</i> , 2004, 39, 871-872.  | 5.8 | 9         |
| 133 | High Rate of Antimicrobial Resistance in <i>Pseudomonas aeruginosa</i> at a Tertiary-Care Teaching Hospital in Southern Brazil. <i>Infection Control and Hospital Epidemiology</i> , 2004, 25, 805-808.                      | 1.8 | 7         |
| 134 | Restricting the use of ampicillin-sulbactam. <i>Journal of Hospital Infection</i> , 2004, 56, 165-166.   | 2.9 | 2         |